Basil P. Hubbard

Basil P. Hubbard

Auto-generated profile, based on publicly available information

Basil P. Hubbard

University of Toronto

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2012 in Cell Metabolism
Verified
Journal Article
Closed access
NPNathan L. Price
Nathan L. Price
AGAna P. Gomes
Ana P. Gomes
ALAlvin J.Y. Ling
Alvin J.Y. Ling
Filipe V DuarteFilipe V Duarte
Filipe V Duarte
Alejandro MartinAlejandro Martin
Alejandro Martin
DSDavid A. Sinclair
David A. Sinclair

1 December 2013 in Cell
Verified
Journal Article
Closed access
AGAna P. Gomes
Ana P. Gomes
NPNathan L. Price
Nathan L. Price
ALAlvin J.Y. Ling
Alvin J.Y. Ling
JMJavid J. Moslehi
Javid J. Moslehi
MMMagdalene Montgomery
Magdalene Montgomery
DSDavid A. Sinclair
David A. Sinclair

19 February 2018 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
KBKhushwant S. Bhullar
Khushwant S. Bhullar
NLNaiara Orrego Lagarón
Naiara Orrego Lagarón
EMEileen McGowan
Eileen McGowan
IPIndu Parmar
Indu Parmar
AJAmitabh Jha
Amitabh Jha
H.P. Vasantha RupasingheH.P. Vasantha Rupasinghe
H.P. Vasantha Rupasinghe
The human genome encodes 538 protein kinases that transfer a γ-phosphate group from ATP to serine, threonine, or tyrosine residues. Many of these kinases are associated with human cancer initiation and progression. The recent development of small-molecule kinase inhibitors for the treatment of diverse types of cancer has proven successful in clinical therapy. Significantly, protein kinases are the second most targeted group of drug targets, after the G-protein-coupled receptors. Since the development of the first protein kinase inhibitor, in the early 1980s, 37 kinase inhibitors have received FDA approval for treatment of malignancies such as breast and lung cancer. Furthermore, about 150 kinase-targeted drugs are in clinical phase trials, and many kinase-specific inhibitors are in the preclinical stage of drug development. Nevertheless, many factors confound the clinical efficacy of these molecules. Specific tumor genetics, tumor microenvironment, drug resistance, and pharmacogenomics determine how useful a compound will be in the treatment of a given cancer. This review provides an overview of kinase-targeted drug discovery and development in relation to oncology and highlights the challenges and future potential for kinase-targeted cancer therapies.

8 March 2013 in Science
Verified
Journal Article
Open access
PDF file
BHBasil P. Hubbard
Basil P. Hubbard
AGAna P. Gomes
Ana P. Gomes
HDHan Dai
Han Dai
JLJun Li
Jun Li
ACApril W. Case
April W. Case
DSDavid A. Sinclair
David A. Sinclair
It's a SIRT: Intense attention has focused on the SIRT1 deacetylase as a possible target for anti-aging drugs. But unexpected complications in assays of SIRT1 activity have made it unclear whether compounds thought to be sirtuin-activating compounds (STACs) are really direct regulators of the enzyme. Further exploration of these effects by Hubbard et al. (p. 1216 ; see the Perspective by Yuan and Marmorstein ) revealed that interaction of SIRT1 with certain substrates allows activation of SIRT1 by STACs and identified critical amino acids in SIRT1 required for these effects. Mouse myoblasts reconstituted with SIRT1 mutated at this amino acid lost their responsiveness to STACs.

1 March 2014 in Trends in Pharmacological Sciences
Verified
Journal Article
Closed access
BHBasil P. Hubbard
Basil P. Hubbard
DSDavid A. Sinclair
David A. Sinclair

18 August 2011 in Scientific Reports
Verified
Journal Article
Open access
RMRobin K. Minor
Robin K. Minor
JBJoseph A. Baur
Joseph A. Baur
AGAna P. Gomes
Ana P. Gomes
TWTheresa M. Ward
Theresa M. Ward
ACAnna Csiszar
Anna Csiszar
RCRafael De Cabo
Rafael De Cabo
Sirt1 is an NAD+-dependent deacetylase that extends lifespan in lower organisms and improves metabolism and delays the onset of age-related diseases in mammals. Here we show that SRT1720, a synthetic compound that was identified for its ability to activate Sirt1 in vitro, extends both mean and maximum lifespan of adult mice fed a high-fat diet. This lifespan extension is accompanied by health benefits including reduced liver steatosis, increased insulin sensitivity, enhanced locomotor activity and normalization of gene expression profiles and markers of inflammation and apoptosis, all in the absence of any observable toxicity. Using a conditional SIRT1 knockout mouse and specific gene knockdowns we show SRT1720 affects mitochondrial respiration in a Sirt1- and PGC-1α-dependent manner. These findings indicate that SRT1720 has long-term benefits and demonstrate for the first time the feasibility of designing novel molecules that are safe and effective in promoting longevity and preventing multiple age-related diseases in mammals.